Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Rhea-AI Summary
Revive Therapeutics (OTCQB: RVVTF) has been approached by a prominent U.S. University Cancer Institute researcher to investigate Bucillamine's potential in cancer treatment, specifically for enhancing anti-tumor effects in advanced solid tumors. The research would be supported by NIH and other government funding.
The investigation builds on existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, which is evaluating Bucillamine for nerve agent exposure treatment. The cancer research focuses on Bucillamine's role as a thiol donor that could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), potentially amplifying antitumor effects.
This approach aims to address challenges in nucleic acid-based therapies, particularly regarding drug delivery and stability in the TME, which is characterized by low oxygen levels and elevated reduced glutathione.
Positive
- New potential application for Bucillamine in cancer treatment expanding market opportunities
- Partnership with prominent U.S. University Cancer Institute researcher
- Research to be funded by NIH and other government entities, reducing company expenses
- Building on existing partnership with Defence R&D Canada, showing multiple potential applications
Negative
- Research is still in early exploratory phase with no guaranteed outcomes
- No timeline provided for research completion or potential commercialization
- Multiple obstacles exist in drug delivery and stability for solid tumor treatments
News Market Reaction – RVVTF
On the day this news was published, RVVTF declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors. This evaluation of Bucillamine in solid tumors would be integrated into a broader study, supported by funding from the NIH and/or other government entities. This proposed research builds on our strategy of evaluating novel uses of Bucillamine in academic and government supporting studies, including the partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, evaluating Bucillamine as a potential treatment for nerve agent exposure. Results from this study are expected shortly.
Rationale of Bucillamine in Cancer
Numerous nucleic acid-based therapies are under development for treating patients with advanced solid tumors. The high death rates linked to these cancers, both in the United States and worldwide, underscore the urgent need for better treatment options. Delivering external nucleic acid-based agents into the tumor microenvironment (“TME”) offers a promising approach to achieving targeted and powerful anti-tumor effects. The TME is marked by low oxygen levels and elevated reduced glutathione, which can destabilize drugs through nanoparticle breakdown in acidic or oxygen-deprived conditions. Additionally, various obstacles hinder both viral and non-viral delivery methods from effectively reaching the TME and releasing their therapeutic cargo. Adjusting the TME’s permeability or retention properties has been proposed as a way to boost the uptake of nucleic acid drugs given systemically, and the influence of these factors on patient outcomes in solid tumor cases remains a key focus of research.1 It is suggested that Bucillamine, a potential non-toxic supplement to certain solid tumor treatments, could act as a thiol donor to neutralize reactive oxygen species, replenish the reduced glutathione in the TME, and thereby amplify antitumor effects, presenting a potential application for this compound.
Michael Frank, CEO of Revive, commented: “We look forward to collaborating with a top U.S. cancer institute to investigate Bucillamine’s potential for solid tumors, confirming its anti-inflammatory and antioxidant effects, since inflammation and oxidative stress are recognized contributors to cancer initiation and growth.”
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “suggested”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three months ended September 30, 2024 ("MD&A"), dated November 29, 2024, which is available on the Company's profile at www.sedarplus.ca.
Source:
- Huayamares SG, Loughrey D, Kim H, Dahlman JE, Sorscher EJ. Nucleic acid-based drugs for patients with solid tumours. Nat Rev Clin Oncol. 2024 Jun;21(6):407-427. doi: 10.1038/s41571-024-00883-1. Epub 2024 Apr 8. PMID: 38589512.
FAQ
What is the new potential application for Bucillamine being investigated by Revive Therapeutics (RVVTF)?
How does Bucillamine (RVVTF) potentially work in cancer treatment?
What partnerships is Revive Therapeutics (RVVTF) currently involved in for Bucillamine research?
What funding sources will support RVVTF's Bucillamine cancer research?
